---
title: "GHK-Cu (Copper Peptide)"
canonical_url: https://peptidelibrary.app/library/ghk-cu
description: "Endogenous glycyl-L-histidyl-L-lysine copper complex used widely in cosmetics for skin remodeling. Injectable research use is unapproved. USADA lists GHK (tripeptide-1) as not prohibited."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# GHK-Cu (Copper Peptide)

GHK-Cu (Copper Peptide), also called Copper tripeptide-1 or GHK copper complex, is a copper tripeptide. GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with high affinity for copper(II), and the copper complex is the biologically active species. Plasma GHK concentrations fall substantially with age, which is the observation the field is built on.

Endogenous glycyl-L-histidyl-L-lysine copper complex used widely in cosmetics for skin remodeling. Injectable research use is unapproved. USADA lists GHK (tripeptide-1) as not prohibited.

Also known as: Copper tripeptide-1, GHK copper complex, Prezatide copper.

Categories: Muscle/Recovery, Cosmetic, Experimental.

## Classification

- Type: Copper tripeptide / cosmetic and research
- Mechanism class: Copper Peptide
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with high affinity for copper(II), and the copper complex is the biologically active species. Plasma GHK concentrations fall substantially with age, which is the observation the field is built on. In skin explant and fibroblast studies the complex modulates expression of matrix metalloproteinases and their tissue inhibitors, stimulates collagen and glycosaminoglycan synthesis, and shifts a broad set of inflammatory and remodelling genes. Copper itself is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, which may account for part of the effect. Most evidence is in vitro or from cosmetic formulation studies rather than controlled clinical trials.

Targets: Copper-dependent enzymes, Extracellular matrix.

Origin: Plasma tripeptide isolated by Pickart; copper(II) complex.

## Properties

- Sequence: Gly-His-Lys (Cu2+ complex)
- Molecular formula: C14H24CuN6O4
- Molecular weight: 403.92 g/mol
- CAS number: 89030-95-5
- Half-life: Short; typically used topically
- Studied routes: Topical

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 1
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 2006

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. 2006. Controlled human trial. Population: Patients undergoing circumoral CO2 laser skin resurfacing. Erythema, wrinkle and overall skin appearance after resurfacing [Source](https://pubmed.ncbi.nlm.nih.gov/16847171/)
2. NCT07437586 — Topical GHK-Cu Gel for Acute Skin Wound Healing. Human study (early or uncontrolled). Population: Adults with acute skin wounds (planned n=60). Acute skin wound healing. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT07437586)

### Registered trials

- [NCT07437586](https://clinicaltrials.gov/study/NCT07437586)

## Safety

Side effects: Blue-green tint at high copper load; Irritation; Injection-site reactions if injected.

Risks: Injectable use is not an approved drug route.

Contraindications: Avoid megadosing; discontinue if irritation occurs.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

GHK-Cu (Copper Peptide) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Permitted
- Availability: Research-Only

## Frequently asked questions

### What is GHK-Cu (Copper Peptide)?

Endogenous glycyl-L-histidyl-L-lysine copper complex used widely in cosmetics for skin remodeling. Injectable research use is unapproved. USADA lists GHK (tripeptide-1) as not prohibited. GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with high affinity for copper(II), and the copper complex is the biologically active species. Plasma GHK concentrations fall substantially with age, which is the observation the field is built on.

### What are the side effects of GHK-Cu (Copper Peptide)?

GHK-Cu (Copper Peptide) has only limited human data, so its side-effect profile is not well established. Effects recorded on this profile include blue-green tint at high copper load, irritation and injection-site reactions if injected. Cautions recorded on this profile: avoid megadosing; discontinue if irritation occurs. This is reference information, not medical advice.

### How does GHK-Cu (Copper Peptide) work?

GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with high affinity for copper(II), and the copper complex is the biologically active species. Plasma GHK concentrations fall substantially with age, which is the observation the field is built on.

### Is GHK-Cu (Copper Peptide) FDA approved?

No. GHK-Cu (Copper Peptide) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A Category 1: Under FDA evaluation (non-injectable routes); 503A nomination: Previously in Category 2; nomination withdrawn by the nominators (injectable routes).

### What is the half-life of GHK-Cu (Copper Peptide)?

Reported half-life for GHK-Cu (Copper Peptide) is Short; typically used topically. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of GHK-Cu (Copper Peptide)?

GHK-Cu (Copper Peptide) has the sequence Gly-His-Lys (Cu2+ complex), giving a chain of 3 amino acids. Its molecular formula is C14H24CuN6O4.

### Is GHK-Cu (Copper Peptide) banned in sport?

GHK-Cu (Copper Peptide) is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### Is GHK-Cu research about injections or skin?

Mostly skin and cell culture. The literature splits into in-vitro work on gene expression and collagen synthesis, topical human studies on skin firmness, fine lines and wound healing, and a thin systemic literature. Clinical evidence sits almost entirely with topical use, so claims of extensive clinical research for injectable GHK-Cu usually point to topical or cell studies.

### Can copper from GHK-Cu build up in the body?

Copper homeostasis is tightly regulated, but copper is an essential trace metal with a toxic ceiling. A topical product delivers a small amount to a limited area; systemic administration is a different exposure question that the topical literature does not address, which is why injectable GHK-Cu warrants more caution than its cosmetic reputation suggests.

## References

- [Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? — Molecules, 2025](https://pubmed.ncbi.nlm.nih.gov/39795193/)
- [Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — Int J Mol Sci, 2018](https://pubmed.ncbi.nlm.nih.gov/29986520/)
- [An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant — Colloids Surf B Biointerfaces, 2025](https://pubmed.ncbi.nlm.nih.gov/40716276/)
- [Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms — Front Pharmacol, 2025](https://pubmed.ncbi.nlm.nih.gov/40672369/)
- [Novel Applications of CE-ICP-MS/MS: Monitoring of Antiaging GHK-Cu Cosmetic Component Encapsulation in Liposomes — Electrophoresis, 2024](https://pubmed.ncbi.nlm.nih.gov/39451062/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
